CA3143030A1 - Methods of treating cancer by targeting cold tumors - Google Patents

Methods of treating cancer by targeting cold tumors Download PDF

Info

Publication number
CA3143030A1
CA3143030A1 CA3143030A CA3143030A CA3143030A1 CA 3143030 A1 CA3143030 A1 CA 3143030A1 CA 3143030 A CA3143030 A CA 3143030A CA 3143030 A CA3143030 A CA 3143030A CA 3143030 A1 CA3143030 A1 CA 3143030A1
Authority
CA
Canada
Prior art keywords
patient
cancer
therapy
tumor
aspects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3143030A
Other languages
English (en)
French (fr)
Inventor
Brian Fox
Ida ARONCHIK
Tracy CHOW
Ellen Filvaroff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of CA3143030A1 publication Critical patent/CA3143030A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3143030A 2019-06-13 2020-06-12 Methods of treating cancer by targeting cold tumors Pending CA3143030A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962861094P 2019-06-13 2019-06-13
US62/861,094 2019-06-13
PCT/US2020/037521 WO2020252331A1 (en) 2019-06-13 2020-06-12 Methods of treating cancer by targeting cold tumors

Publications (1)

Publication Number Publication Date
CA3143030A1 true CA3143030A1 (en) 2020-12-17

Family

ID=73781074

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3143030A Pending CA3143030A1 (en) 2019-06-13 2020-06-12 Methods of treating cancer by targeting cold tumors

Country Status (10)

Country Link
US (1) US12357633B2 (https=)
EP (1) EP3983016A4 (https=)
JP (1) JP2022536412A (https=)
KR (1) KR20220024426A (https=)
CN (1) CN115135324A (https=)
AU (1) AU2020290508A1 (https=)
CA (1) CA3143030A1 (https=)
IL (1) IL288939A (https=)
MX (1) MX2021015447A (https=)
WO (1) WO2020252331A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113421613A (zh) * 2021-06-08 2021-09-21 吴安华 一种基于铁死亡水平评价胶质母细胞瘤患者免疫治疗反应性的系统及分析方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4114398A1 (en) * 2020-03-06 2023-01-11 Celgene Quanticel Research, Inc. Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc
AU2024337882A1 (en) * 2023-09-07 2026-02-19 Sutter Bay Hospitals Co-targeting ncoa3 and pd-1 for cancer therapy
CN117538544A (zh) * 2023-11-22 2024-02-09 湛江中心人民医院 检测基因Ccdc181表达量的试剂在制备精子异常诊断产品中的应用
KR20250143182A (ko) * 2024-03-21 2025-10-01 차의과학대학교 산학협력단 시스플라틴에 대한 반응성의 예후를 나타내는 비소세포폐암 환자의 분류를 위한 분석방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160116474A1 (en) * 2013-06-20 2016-04-28 The Broad Institute, Inc. Compositions and methods for detecting and treating glioblastoma
KR102400920B1 (ko) 2014-05-01 2022-05-20 셀젠 콴티셀 리서치, 인크. 리신 특이적 데메틸라제-1의 억제제
LT3371152T (lt) * 2015-11-05 2021-04-12 Celgene Quanticel Research, Inc. Kompozicijos, apimančios lizinui specifinės demetilazės-1 inhibitorių, turinčios pirimidino žiedą, ir jų panaudojimas vėžio gydymui
US11998540B2 (en) * 2015-12-11 2024-06-04 The General Hospital Corporation Compositions and methods for treating drug-tolerant glioblastoma
ES2972741T3 (es) 2016-08-10 2024-06-14 Celgene Quanticel Res Inc Tratamiento del carcinoma de células de Merkel
MA51507A (fr) * 2016-12-09 2020-11-11 Constellation Pharmaceuticals Inc Marqueurs pour un traitement personnalisé du cancer avec des inhibiteurs de lsd1
WO2019083971A1 (en) * 2017-10-23 2019-05-02 Children's Medical Center Corporation METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113421613A (zh) * 2021-06-08 2021-09-21 吴安华 一种基于铁死亡水平评价胶质母细胞瘤患者免疫治疗反应性的系统及分析方法

Also Published As

Publication number Publication date
MX2021015447A (es) 2022-04-06
AU2020290508A1 (en) 2022-01-27
IL288939A (en) 2022-02-01
KR20220024426A (ko) 2022-03-03
US12357633B2 (en) 2025-07-15
WO2020252331A1 (en) 2020-12-17
EP3983016A1 (en) 2022-04-20
US20220273654A1 (en) 2022-09-01
JP2022536412A (ja) 2022-08-16
CN115135324A (zh) 2022-09-30
EP3983016A4 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
US12357633B2 (en) Methods of treating cancer by targeting cold tumors
US20220308054A1 (en) Methods of determining prognosis of sepsis and treating same
US10570457B2 (en) Methods for predicting drug responsiveness
US10927410B2 (en) Compositions and methods for identification, assessment, prevention, and treatment of T-cell exhaustion using CD39 biomarkers and modulators
EP4417708B1 (en) Methods for assessing risk of developing a viral disease using a genetic test
TW201938796A (zh) 使用atr抑制劑治療癌症之方法
CA2714410A1 (en) Disease markers and uses thereof
US20220185886A1 (en) Methods for identifying biomarkers to predict treatment response
US11568959B2 (en) Tumor microenvironment-based methods for assessing CAR-T and other immunotherapies
JP2022536412A5 (https=)
EP3921443A1 (en) Diagnostic and therapeutic methods for cancer
US20220380854A1 (en) ANGIOGENESIS AND mMDSC GENE EXPRESSION BASED BIOMARKER OF TUMOR RESPONSE TO PD-1 ANTAGONISTS
Guo et al. Cyclin-dependent kinase inhibition and its intersection with immunotherapy in breast cancer: more than CDK4/6 inhibition
KR20250163916A (ko) 비소세포 폐암의 예후 및 치료 방법
US20250387425A1 (en) Novel personal neoantigen vaccines and markers
US20200385478A1 (en) Compositions and methods for cancer immunotherapy
US12560609B2 (en) Biomarkers predictive of cancer cell response to ML329 or a derivative thereof
Cui et al. Identification of ATM mutation as a potential prognostic biomarker for immune checkpoint inhibitors therapy
Ibarra et al. Overview and Current News in Acute Lymphoblastic Leukemia
Paoli Characterization of the antitumor activity of the PI3K δ-sparing inhibitor MEN1611 mediated by the PIK3γ inhibition on macrophages and tumour immune infiltrate
US12173039B1 (en) TPL2 inhibiting agents, uses thereof, and detection of TPL2
EP3255433A1 (en) Methods using blm as a marker of multiple myeloma
RU2813966C2 (ru) Способы лечения злокачественных опухолей с использованием ингибитора atr
US20250179584A1 (en) Precision therapy for the treatment of cancer
Clark et al. An aza-anthrapyrazole negatively regulates Th1 activity and suppresses experimental autoimmune encephalomyelitis

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251205

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260129

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260205